Featured Research

from universities, journals, and other organizations

Clinical trial of medication to treat NF2 tumors starting soon

Date:
February 12, 2013
Source:
House Research Institute
Summary:
Researchers are recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

Mouse schwannoma cell in culture.
Credit: Image courtesy of House Research Institute

House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

NF2 is a genetic disease characterized by noncancerous tumors in the central nervous system. The disease occurs in 1 in 25,000 births in the United States. A diagnosis of NF2 is made when tumors, called vestibular schwannomas or acoustic neuromas, are found on both auditory nerves. The growth of the tumors can lead to hearing loss, facial paralysis and balance difficulties because the tumors are located on the auditory, balance, and facial nerves. When the tumors are surgically removed, patients are often left completely deaf.

"With few treatment options available other than surgery for patients with NF2, we often watch the tumors and wait as long as possible before operating. Although surgery removes the tumor, we often have to cut the patient's auditory nerve leaving the patient deaf in that ear," said Derald Brackmann, M.D., House Clinic Associate and Co-Investigator.

The clinical trial is investigating the medication RAD001 (everolimus), an analog of Rapamycin, to see if the drug is effective in slowing the growth of the vestibular schwannomas in NF2 patients. The pre-clinical research results are promising.

"It was an exciting moment when we first saw the potential effect of this drug on NF2 tumors in our preclinical NF2 mouse model. It is a good candidate for clinical trials in humans," said Marco Giovannini, M.D., Ph.D., House Research Institute Principal Investigator.

To be eligible to participate in the study, patients must have at least one vestibular schwannoma, which has shown growth in the prior 12 month time period. Patients must also be between 16 and 65 years-old. Up to 25 patients will be enrolled in the clinical trial.

"It is a privilege to work with world leaders in the NF2 field to bring this molecular targeted therapy to patients," said Joni Doherty, M.D., Ph.D., House Research Institute Co-Investigator.

The study consists of taking RAD001 orally for 12 months or until the tumor shows growth. Tumor growth will be monitored with several MRI scans throughout the 12 months of the study.

In addition to the primary objective of the trial, the secondary objective is to see if RAD001 slows the growth of other central nervous system tumors the patients may have and to see if the patients experience any changes in their hearing.

For more information on the clinical trial, please visit http://clinicaltrials.gov/show/NCT01345136.


Story Source:

The above story is based on materials provided by House Research Institute. Note: Materials may be edited for content and length.


Cite This Page:

House Research Institute. "Clinical trial of medication to treat NF2 tumors starting soon." ScienceDaily. ScienceDaily, 12 February 2013. <www.sciencedaily.com/releases/2013/02/130212111729.htm>.
House Research Institute. (2013, February 12). Clinical trial of medication to treat NF2 tumors starting soon. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2013/02/130212111729.htm
House Research Institute. "Clinical trial of medication to treat NF2 tumors starting soon." ScienceDaily. www.sciencedaily.com/releases/2013/02/130212111729.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins